Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)

Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy. M‐mode echocardiography and plasma hormone concentrations were available...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cardiology (Mahwah, N.J.) N.J.), 1994-11, Vol.17 (11), p.603-606
Hauptverfasser: Eriksson, S. V., Eneroth, P., Kjekshus, J., Offstad, J., Swedberg, K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 606
container_issue 11
container_start_page 603
container_title Clinical cardiology (Mahwah, N.J.)
container_volume 17
creator Eriksson, S. V.
Eneroth, P.
Kjekshus, J.
Offstad, J.
Swedberg, K.
description Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy. M‐mode echocardiography and plasma hormone concentrations were available at baseline and after 6 weeks of treatment. There was a significant relationship between LV systolic function and levels of angiotensin‐II and norepinephrine. Enalapril increased LV fractional shortening (FS%) (13.3±5.6 to 15.4±5.8, p
doi_str_mv 10.1002/clc.4960171107
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77700510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77700510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4467-7852c9a5fc0bb67961da4adfeb259233d2d86442d4f6d10fc1f2225cb0f2e4dc3</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS0EKmlhyw7JK0QXE2yPM55hV43KjxSli9D1yGNfN0aOHezxoDwlr4RLws-Ola90v_PJVwehV5QsKSHsnXJqybuGUEEpEU_QgnY1q1pRi6doQWhDqo613XN0mdLXwpOW1RfoQrQ172q-QD82kGMAr4OK1gOWarKznGzw2HocwZ3mKWAHZsIz-ClalZ2M2GSvfoNqF4O3CieYIQJWwT9AKibAO5BxwkZalyO8xzc45fEhhnzA0kt3TDZhE8MeT7vHWDhAlL9yPsRph5OSXlsvZys9hhKQh2hdccS5fLMMU9ZH_La_22xvN9v77fUL9MxIl-Dl-b1C9x9uv_SfqvXdx8_9zbpSnDeiEu2KqU6ujCLj2IiuoVpyqQ2MbNWxutZMtw3nTHPTaEqMooYxtlIjMQy4VvUVenPyHmL4lsutw94mBc5JDyGnQQhByIqSAi5PoIohpQhmKBfsZTwOlAyPDQ6lweFvgyXw-mzO4x70H_xcWdl3p_136-D4H9vQr_t_3D8Ba0it8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77700510</pqid></control><display><type>article</type><title>Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Eriksson, S. V. ; Eneroth, P. ; Kjekshus, J. ; Offstad, J. ; Swedberg, K.</creator><creatorcontrib>Eriksson, S. V. ; Eneroth, P. ; Kjekshus, J. ; Offstad, J. ; Swedberg, K.</creatorcontrib><description>Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy. M‐mode echocardiography and plasma hormone concentrations were available at baseline and after 6 weeks of treatment. There was a significant relationship between LV systolic function and levels of angiotensin‐II and norepinephrine. Enalapril increased LV fractional shortening (FS%) (13.3±5.6 to 15.4±5.8, p&lt;0.05) and decreased the systolic time interval index (0.58±0.14 to 0.48 ± 0.15, p &lt; 0.05) concurrent with a significant decrease in angiotensin‐converting enzyme activity and in aldosterone, angiotensin‐II, and norepinephrine concentrations after 6 weeks. No changes were found in the placebo group. However, there was no direct relationship between the amount of change in neurohormones and improvement in LV function after 6 weeks. These findings indicate that in patients with severe chronic CHF, severe LV systolic dysfunction is associated with high plasma levels of angiotensin‐II and norepinephrine, which can be favorably modified by enalapril. This may be of importance for prolonging life in severe heart failure. The lack of relationship between changes in individual hormones and systolic function suggests complex dynamic interaction. It is, therefore, not sufficient to predict changes in LV function by measuring changes in only one hormone.</description><identifier>ISSN: 0160-9289</identifier><identifier>EISSN: 1932-8737</identifier><identifier>DOI: 10.1002/clc.4960171107</identifier><identifier>PMID: 7834934</identifier><language>eng</language><publisher>New York: Wiley Periodicals, Inc</publisher><subject>Aldosterone - blood ; angiotensinconverting enzyme inhibitor ; congestive heart failure ; Echocardiography ; Enalapril - therapeutic use ; Heart Failure - blood ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Heart Ventricles - drug effects ; Heart Ventricles - physiopathology ; hormones ; Humans ; left ventricular systolic function ; Neurosecretory Systems - physiopathology ; Norepinephrine - blood</subject><ispartof>Clinical cardiology (Mahwah, N.J.), 1994-11, Vol.17 (11), p.603-606</ispartof><rights>Copyright © 1994 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4467-7852c9a5fc0bb67961da4adfeb259233d2d86442d4f6d10fc1f2225cb0f2e4dc3</citedby><cites>FETCH-LOGICAL-c4467-7852c9a5fc0bb67961da4adfeb259233d2d86442d4f6d10fc1f2225cb0f2e4dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fclc.4960171107$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fclc.4960171107$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7834934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eriksson, S. V.</creatorcontrib><creatorcontrib>Eneroth, P.</creatorcontrib><creatorcontrib>Kjekshus, J.</creatorcontrib><creatorcontrib>Offstad, J.</creatorcontrib><creatorcontrib>Swedberg, K.</creatorcontrib><title>Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)</title><title>Clinical cardiology (Mahwah, N.J.)</title><addtitle>Clin Cardiol</addtitle><description>Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy. M‐mode echocardiography and plasma hormone concentrations were available at baseline and after 6 weeks of treatment. There was a significant relationship between LV systolic function and levels of angiotensin‐II and norepinephrine. Enalapril increased LV fractional shortening (FS%) (13.3±5.6 to 15.4±5.8, p&lt;0.05) and decreased the systolic time interval index (0.58±0.14 to 0.48 ± 0.15, p &lt; 0.05) concurrent with a significant decrease in angiotensin‐converting enzyme activity and in aldosterone, angiotensin‐II, and norepinephrine concentrations after 6 weeks. No changes were found in the placebo group. However, there was no direct relationship between the amount of change in neurohormones and improvement in LV function after 6 weeks. These findings indicate that in patients with severe chronic CHF, severe LV systolic dysfunction is associated with high plasma levels of angiotensin‐II and norepinephrine, which can be favorably modified by enalapril. This may be of importance for prolonging life in severe heart failure. The lack of relationship between changes in individual hormones and systolic function suggests complex dynamic interaction. It is, therefore, not sufficient to predict changes in LV function by measuring changes in only one hormone.</description><subject>Aldosterone - blood</subject><subject>angiotensinconverting enzyme inhibitor</subject><subject>congestive heart failure</subject><subject>Echocardiography</subject><subject>Enalapril - therapeutic use</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Ventricles - drug effects</subject><subject>Heart Ventricles - physiopathology</subject><subject>hormones</subject><subject>Humans</subject><subject>left ventricular systolic function</subject><subject>Neurosecretory Systems - physiopathology</subject><subject>Norepinephrine - blood</subject><issn>0160-9289</issn><issn>1932-8737</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uEzEUhS0EKmlhyw7JK0QXE2yPM55hV43KjxSli9D1yGNfN0aOHezxoDwlr4RLws-Ola90v_PJVwehV5QsKSHsnXJqybuGUEEpEU_QgnY1q1pRi6doQWhDqo613XN0mdLXwpOW1RfoQrQ172q-QD82kGMAr4OK1gOWarKznGzw2HocwZ3mKWAHZsIz-ClalZ2M2GSvfoNqF4O3CieYIQJWwT9AKibAO5BxwkZalyO8xzc45fEhhnzA0kt3TDZhE8MeT7vHWDhAlL9yPsRph5OSXlsvZys9hhKQh2hdccS5fLMMU9ZH_La_22xvN9v77fUL9MxIl-Dl-b1C9x9uv_SfqvXdx8_9zbpSnDeiEu2KqU6ujCLj2IiuoVpyqQ2MbNWxutZMtw3nTHPTaEqMooYxtlIjMQy4VvUVenPyHmL4lsutw94mBc5JDyGnQQhByIqSAi5PoIohpQhmKBfsZTwOlAyPDQ6lweFvgyXw-mzO4x70H_xcWdl3p_136-D4H9vQr_t_3D8Ba0it8g</recordid><startdate>199411</startdate><enddate>199411</enddate><creator>Eriksson, S. V.</creator><creator>Eneroth, P.</creator><creator>Kjekshus, J.</creator><creator>Offstad, J.</creator><creator>Swedberg, K.</creator><general>Wiley Periodicals, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199411</creationdate><title>Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)</title><author>Eriksson, S. V. ; Eneroth, P. ; Kjekshus, J. ; Offstad, J. ; Swedberg, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4467-7852c9a5fc0bb67961da4adfeb259233d2d86442d4f6d10fc1f2225cb0f2e4dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Aldosterone - blood</topic><topic>angiotensinconverting enzyme inhibitor</topic><topic>congestive heart failure</topic><topic>Echocardiography</topic><topic>Enalapril - therapeutic use</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Ventricles - drug effects</topic><topic>Heart Ventricles - physiopathology</topic><topic>hormones</topic><topic>Humans</topic><topic>left ventricular systolic function</topic><topic>Neurosecretory Systems - physiopathology</topic><topic>Norepinephrine - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eriksson, S. V.</creatorcontrib><creatorcontrib>Eneroth, P.</creatorcontrib><creatorcontrib>Kjekshus, J.</creatorcontrib><creatorcontrib>Offstad, J.</creatorcontrib><creatorcontrib>Swedberg, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eriksson, S. V.</au><au>Eneroth, P.</au><au>Kjekshus, J.</au><au>Offstad, J.</au><au>Swedberg, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)</atitle><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle><addtitle>Clin Cardiol</addtitle><date>1994-11</date><risdate>1994</risdate><volume>17</volume><issue>11</issue><spage>603</spage><epage>606</epage><pages>603-606</pages><issn>0160-9289</issn><eissn>1932-8737</eissn><abstract>Left ventricular (LV) function and plasma levels of cardiovascular hormones were examined in patients with severe chronic congestive heart failure (CHF), randomized to placebo or enalapril, in addition to conventional therapy. M‐mode echocardiography and plasma hormone concentrations were available at baseline and after 6 weeks of treatment. There was a significant relationship between LV systolic function and levels of angiotensin‐II and norepinephrine. Enalapril increased LV fractional shortening (FS%) (13.3±5.6 to 15.4±5.8, p&lt;0.05) and decreased the systolic time interval index (0.58±0.14 to 0.48 ± 0.15, p &lt; 0.05) concurrent with a significant decrease in angiotensin‐converting enzyme activity and in aldosterone, angiotensin‐II, and norepinephrine concentrations after 6 weeks. No changes were found in the placebo group. However, there was no direct relationship between the amount of change in neurohormones and improvement in LV function after 6 weeks. These findings indicate that in patients with severe chronic CHF, severe LV systolic dysfunction is associated with high plasma levels of angiotensin‐II and norepinephrine, which can be favorably modified by enalapril. This may be of importance for prolonging life in severe heart failure. The lack of relationship between changes in individual hormones and systolic function suggests complex dynamic interaction. It is, therefore, not sufficient to predict changes in LV function by measuring changes in only one hormone.</abstract><cop>New York</cop><pub>Wiley Periodicals, Inc</pub><pmid>7834934</pmid><doi>10.1002/clc.4960171107</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0160-9289
ispartof Clinical cardiology (Mahwah, N.J.), 1994-11, Vol.17 (11), p.603-606
issn 0160-9289
1932-8737
language eng
recordid cdi_proquest_miscellaneous_77700510
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Alma/SFX Local Collection
subjects Aldosterone - blood
angiotensinconverting enzyme inhibitor
congestive heart failure
Echocardiography
Enalapril - therapeutic use
Heart Failure - blood
Heart Failure - drug therapy
Heart Failure - physiopathology
Heart Ventricles - drug effects
Heart Ventricles - physiopathology
hormones
Humans
left ventricular systolic function
Neurosecretory Systems - physiopathology
Norepinephrine - blood
title Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T06%3A04%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroendocrine%20activation%20in%20relation%20to%20left%20ventricular%20function%20in%20chronic%20severe%20congestive%20heart%20failure:%20A%20subgroup%20analysis%20from%20the%20cooperative%20north%20scandinavian%20enalapril%20survival%20study%20(CONSENSUS)&rft.jtitle=Clinical%20cardiology%20(Mahwah,%20N.J.)&rft.au=Eriksson,%20S.%20V.&rft.date=1994-11&rft.volume=17&rft.issue=11&rft.spage=603&rft.epage=606&rft.pages=603-606&rft.issn=0160-9289&rft.eissn=1932-8737&rft_id=info:doi/10.1002/clc.4960171107&rft_dat=%3Cproquest_cross%3E77700510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77700510&rft_id=info:pmid/7834934&rfr_iscdi=true